Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02822339 · ClinicalTrials.gov registry record · NA

Sun Protection Factor Assay

A NA study of Sunscreening Agents, sponsored by Bayer.

Completed
Registry status
NA
Development phase
5
Enrollment target
1
Study location

NCT02822339: Completed NA study of Sunscreening Agents, sponsored by Bayer.

NCT02822339 is a NA study of Sunscreening Agents that has completed, run by Bayer. The registered enrollment target is 5 participants, below the 81-participant average among 21 other Sunscreening Agents trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02822339, a NA study of Sunscreening Agents, has completed, sponsored by Bayer.

COMPLETED
Registry status
NA
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

To evaluate the Sun Protection Factor efficacy on human skin.

Conditions Studied

Interventions

  • DRUG BAY987517

Study Locations (1)

New Jersey

  • - Union

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2016-06-23
Est. Completion 2016-06-29
Phase NA
Bayer

591 total trials

What the finished NCT02822339 record still lists

NCT02822339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 81-participant average among 21 other Sunscreening Agents trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Sunscreening Agents appearing as the primary indexed condition, and to 1 intervention - of which BAY987517 is the first listed.

NCT02822339 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT02822339 about?

NCT02822339 is a clinical study titled "Sun Protection Factor Assay". To evaluate the Sun Protection Factor efficacy on human skin.

What is the current status of trial NCT02822339?

This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2016-06-23. Estimated completion is 2016-06-29.

What conditions does trial NCT02822339 study?

This clinical trial studies the following conditions: Sunscreening Agents.

What interventions are being tested in trial NCT02822339?

The interventions under investigation include: BAY987517 (DRUG).

Who is sponsoring clinical trial NCT02822339?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02822339 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sunscreening Agents

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02822339's enrollment target sits among peer trials

5 20th of 21 higher than 2 of 21 other Sunscreening Agents trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sunscreening Agents trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02822339, the US trial registry maintained by the National Library of Medicine. NCT02822339 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.